With the Covid-19 outbreak, echocardiography being a bedside technique, is likely to be used often for the detection of cardiac dysfunction (global/regional) and identification of LV thrombus as Covid-19 has been shown to increase thrombogenicity. Hence, echo contrast agents are likely to be used. However, no data exist regarding its usefulness and safety in Covid-19 patients.
This registry in the form of a short survey is to establish its utility and safety in Covid-19 patients.
The survey ends on 31 August.
 
Before we begin, may we just remind you of our Code of Conduct for ESC surveys?
• Your participation is anonymous.
• You have the right to end your participation in this survey at any time.
• We comply with the European General Data Protection Regulation (GDPR) 2016/679. The data will only be used by the ESC, for the purpose of market research and not for promotion, and will be kept for a maximum of 24 months. If you have any questions about data protection or require further information, please contact our data protection officer (DPO) at dpo@escardio.org.

Question Title

* 2. Indication for Echocardiography

Question Title

* 3. Indications for contrast echocardiography

Question Title

* 4. Contrast agent administered

Question Title

* 5. Location in the hospital

Question Title

* 6. Age

Question Title

* 7. Gender

Question Title

* 8. Cardiac co-morbidity

Question Title

* 9. Symptoms

Question Title

* 10. Severity of symptoms

Question Title

* 11. Hemodynamic status

Question Title

* 12. Condition of patient

Question Title

* 13. Blood markers

Question Title

* 14. Did contrast echocardiography change the management?

Question Title

* 15. Complications following Contrast Echocardiography

Question Title

* 16. Any other comment

0 of 16 answered
 

T